Week In Review: How Trump's Policies Moved Stocks- Week Of Dec. 14-18

Trump Tower, Building, City, Urban, Trump, Cityscape

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump and his administration with this weekly recap compiled by The Fly.

DEFENSE BILL

President Trump said via Twitter that, "I will Veto the Defense Bill, which will make China very unhappy. They love it. Must have Section 230 termination, protect our National Monuments and allow for removal of military from far away, and very unappreciative, lands." Publicly traded defense contractors include BAE Systems (BAESY), Boeing (BA), General Dynamics (GD), Lockheed Martin (LMT), Merged into RTX (RTN), Merged into RTX (UTX) and Northrop Grumman (NOC).

MORE PFIZER COVID VACCINE DOSES: Pfizer (PFE) and the Trump administration are in discussions that would help the drugmaker get raw materials to manufacture more COVID-19 vaccine doses next year, Sharon LaFraniere, Katie Thomas and Noah Weiland of The New York Times reported, citing people familiar with the situation. The added capacity would allow Pfizer to produce tens of millions of additional doses of its Covid-19 vaccine for Americans in the first half of 2021, the report stated.

MODERNA VACCINE

Moderna (MRNA) announced that the Food and Drug Administration's has authorized the emergency use of mRNA-1273, Moderna's vaccine against COVID-19 in individuals 18 years of age or older. The Moderna COVID-19 Vaccine is now authorized for distribution and use under an Emergency Use Authorization. Delivery to the U.S. Government will begin immediately, the company said. Approximately 20M doses will be delivered to the U.S. government by the end of December. The company expects to have between 100M and 125M doses available globally in the first quarter of 2021, with 85M to 100M of those available in the U.S.

On Friday morning, President Trump had tweeted that the vaccine was "overwhelmingly approved" and that distribution would "start immediately," though an FDA spokesperson told Bloomberg soon after that that the vaccine's emergency use authorization remained under review and that had not yet been authorized as of the time of the tweet.

1 2
View single page >> |

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at  more

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.